CONTOUR® Structure-Based Drug Design

Vitae is developing pharmaceutical product candidates through the use of a proprietary structure-based drug design platform called Contour®.


Vitae Pharmaceuticals has expertise in the field of structure-based drug design (SBDD). Vitae has developed proprietary expertise in structure-based drug design, most notably an industry-leading SBDD platform, called , which serves as the foundation for the company’s drug discovery efforts. Contour® computationally builds a drug-like molecule in the active site of a protein target one fragment at a time and then predicts how tightly that molecule binds to the protein. The company’s team of scientists leverages Contour® to create and advance innovative drugs for the treatment of diseases with unmet medical needs, including diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome.

Vitae utilizes its Contour® structure-based drug design platform to discover and develop product candidates for validated therapeutic targets against which the industry has traditionally struggled to develop drugs due to challenges related to potency, selectivity, pharmacokinetics, or patentability. Vitae Pharmaceuticals refers to these as “difficult-to-drug.” This gives Vitae Pharmaceuticals’ scientists the ability to create best-in-class or first-in-class drugs for challenging targets with attractive drug-like properties. This includes highly potent and selective product candidates and drugs that are consistent with once-a-day dosing in humans.

The company’s Contour® SBDD has successfully delivered programs on several very difficult targets, including 11ß-HSD-1, beta-secretase and the nuclear hormone receptors ROR and LXR. The platform has consistently generated novel, patentable leads within 2-6 months and animal proof-of-concept data in less than 18 months from the initiation of a program.

Contour® is Vitae’s proprietary SBDD technology platform that the company‘s team of scientists leverages to discover and develop product candidates for “difficult-to-drug” targets.